Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Researchers from the University of Pennsylvania’s Abramson Cancer Center administered CAR T cells to patients following chemotherapy, with 64 percent of patients responding in a clinical trial. Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Researchers from the University of Pennsylvania’s Abramson Cancer Center administered CAR T cells to patients following chemotherapy, with 64 percent of patients responding in a clinical trial.
In a separate study, patients got an infusion of an experimental monoclonal antibody, which resulted in an overall response rate of 60 percent. Both of these investigational approaches targeted a receptor called B-Cell Maturation Antigen (BCMA), which is highly expressed in myeloma and thus a promising target for treatment. These studies were presented as oral abstracts at the 59th Annual American Society of Hematology Meeting and Exposition in Atlanta.
Read the Department of Communications news release